



HEALTHCARE

The Asthma and COPD Market Outlook

Market analysis of future growth and leading players by sector

 [Table of Contents](#)

Copyright © 2004 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any
purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of
Business Insights. Business Insights Ltd accepts no liability for the accuracy or
completeness of the information, advice or comment contained in this Management
Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of
publication, no responsibility can be accepted by Business Insights Ltd for its
completeness or accuracy.

Table of Contents

The Asthma and COPD Market Outlook: Market analysis of future growth and leading players by sector

Executive summary	10
Epidemiology analysis	10
Global asthma/COPD market analysis	11
First/second-line treatment market analysis	12
Third-line asthma treatments market analysis	13
Leading players in the asthma/COPD market	14
Chapter 1 Epidemiology analysis	16
Summary	16
Introduction	17
Disease description	17
Asthma	17
Chronic Obstructive Pulmonary Disease	18
Disease classification	18
Asthma	18
COPD	20
Current and future prevalence of asthma/COPD	20
Asthma	20
COPD	23
Diagnosis	26
Asthma	26
COPD	28
Current and future treatment patterns	28

Chapter 2 Global asthma/COPD market analysis 34

Summary	34
Introduction	35
History of asthma drugs	35
Current growth drivers	36
SABA/LABA treatments	37
ICS	37
Xanthines	38
Oral corticosteroids	38
Combination therapies	39
Anticholinergics and leukotriene antagonists	39
Future growth drivers	40
Monoclonal antibodies	40
Anti-muscarinics	40

Chapter 3 First and second-line therapies: Beta-2 agonists, ICS and combination ICS/LABA drugs 42

Summary	42
Introduction	43
First and second-line treatment categories and sales	43
Company market share	44
Brand market share and sales	46
SABA/LABA treatments	51
Brand analysis	51
Serevent (salmeterol xinfoate)	51
Xopenex (levalbuterol)	53
Ventolin (salbutamol/albuterol)	55
Foradil (formoterol fumarate)	56
ICS treatments	57
Brand analysis	57
Flixotide/Flovent (fluticasone propionate)	58
Pulmicort (budesonide)	59
LABA/ICS combination treatments	61
Brand analysis	61
Seretide/Advair (fluticasone propionate and salmeterol xinfoate)	61
Symbicort (budesonide and formoterol)	63

AstraZeneca	97
Therapeutic focus	97
Marketed products	97
R&D pipeline	98
Novartis	99
Therapeutic focus	99
Marketed products	99
R&D pipeline	100
Xolair (omalizumab)	100
QAB149	101
Sepracor	102
Therapeutic focus	102
Marketed products	102
R&D pipeline	103
Alformoterol	103
Altana	104
Therapeutic focus	104
Marketed products	105
R&D pipeline	105
Alvesco (ciclesonide)	105
Daxas (roflumilast)	106
Index	109

List of Figures

Figure 1.1:	Estimated relative prevalence of asthma patients by severity, 2003	19
Figure 1.2:	Estimated variation in the prevalence of asthma in the US & five major European markets, 2003	21
Figure 1.3:	Estimated prevalence of asthma in the US & 5 major European markets, 2003-2013	22
Figure 1.4:	Estimated variation in the prevalence of COPD in the US & 5 major European markets, 2003	24
Figure 1.5:	Estimated prevalence of COPD in the US & 5 major European markets, 2003-2013	25
Figure 1.6:	Estimated proportion of patients presenting with asthma that are correctly diagnosed by visit	27
Figure 1.7:	Typical treatment patterns in the treatment of asthma	29
Figure 1.8:	Estimated proportion of patients on leading therapeutic classes of drugs used in the treatment of asthma by disease severity, 2003	30
Figure 2.9:	Development timeline for major asthma/COPD drugs and classes	35
Figure 3.10:	Asthma/COPD first/second-line brands by company and type, 2004	46
Figure 3.11:	US/European* market share of leading inhaled corticosteroid brands (%), 1999-2003	47
Figure 3.12:	US/European* market share of leading inhaled beta-2 agonist brands (%), 1999-2003	48
Figure 3.13:	US/European* market share of leading inhaled beta-2 agonist brands (%), 1999-2003	49
Figure 3.14:	Serevent SWOT analysis	52
Figure 3.15:	Xopenex SWOT analysis	54
Figure 3.16:	Ventolin SWOT analysis	55
Figure 3.17:	Foradil SWOT analysis	56
Figure 3.18:	Flixotide/Flovent SWOT analysis	59
Figure 3.19:	Pulmicort SWOT analysis	60
Figure 3.20:	Seretide/Advair SWOT analysis	62
Figure 3.21:	Symbicort SWOT analysis	64
Figure 4.22:	Asthma/COPD third-line brands by company and type, 2004	70
Figure 4.23:	US/European* market share of leading leukotriene antagonist brands (%), 1999-2003	71
Figure 4.24:	US/European* market share of leading anticholinergic and SABA/anticholinergic combination products (%), 1999-2003	72
Figure 4.25:	Singulair SWOT analysis	76
Figure 4.26:	Combivent SWOT analysis	78
Figure 4.27:	Atrovent SWOT analysis	79
Figure 4.28:	Spiriva SWOT analysis	80
Figure 5.29:	Merck's forecast therapeutic focus, 2003-2010	86
Figure 5.30:	GSK's therapeutic focus, 2003-2010	89
Figure 5.31:	Boehringer Ingelheim's therapeutic focus, 2003 & 2010	93
Figure 5.32:	Schering-Plough's forecast therapeutic focus, 2003-10	95
Figure 5.33:	AstraZeneca's forecast therapeutic focus, 2003-10	97
Figure 5.34:	Novartis' forecast therapeutic focus, 2003-10	99
Figure 5.35:	Altana's forecast therapeutic focus, 2003-10	104

List of Tables

Table 1.1:	Classification of asthma sufferers according to disease severity	19
Table 1.2:	Estimated prevalence of asthma in children and adults across the US & 5 European markets, 2003	21
Table 1.3:	Estimated prevalence of asthma in the US & 5 major European markets, 2003-2013	23
Table 1.4:	Estimated prevalence of adult COPD in the US & 5 major European markets, 2003-2013	26
Table 1.5:	Estimates of the number and proportion of patients receiving asthma treatments by drug class, 2003	31
Table 1.6:	US and European* Sales by Drug Class (\$m), 2002-2003	32
Table 2.7:	US/European* sales category totals (\$m), 2002-2003	36
Table 3.8:	US/European* Sales of first and second-line asthma/COPD treatments by category (\$m), 2002-2003	44
Table 3.9:	First/second-line therapy market share by company and territory (%), 2002-2003	45
Table 3.10:	Sales of leading 1st/2nd-line treatments by country (\$m), 2002-03	50
Table 3.11:	Branded SABA/LABA treatments	51
Table 3.12:	Branded ICS treatments	57
Table 3.13:	Branded LABA/ICS combination treatments	61
Table 4.14:	US/European* Sales of third-line asthma/COPD treatments by category (\$m), 2002-2003	68
Table 4.15:	Third-line therapy market share by company and territory (%), 2002-2003	69
Table 4.16:	Sales of major branded third-line treatments by country, 2002-03	73
Table 4.17:	Major branded leukotriene antagonist treatments	75
Table 4.18:	Branded ACh and SABA/ACh treatments	77
Table 5.19:	US/European* asthma/COPD market share by company (%), 2002-03	85
Table 5.20:	US/European* leukotriene antagonist market share by company (%), 2002-03	87
Table 5.21:	US/European* sales of Merck & Co's marketed asthma/COPD portfolio (\$m), 2002-2003	88
Table 5.22:	Projected sales of Merck's asthma/COPD R&D pipeline (\$m), 2007 & 2010	88
Table 5.23:	US/European* first/second-line treatment market share by company (%), 2002-2003	90
Table 5.24:	US/European* sales of GSK's marketed asthma/COPD portfolio (\$m), 2002-2003	90
Table 5.25:	Projected sales of GSK's asthma/COPD R&D pipeline (\$m), 2007 & 2010	91
Table 5.26:	US/European* anticholinergic treatment market share by company (%), 2002-2003	94
Table 5.27:	US/European* sales of Boehringer Ingelheim's marketed asthma/COPD portfolio (\$m), 2002-2003	94
Table 5.28:	US/European* sales of Schering-Plough's marketed asthma/COPD portfolio (\$m), 2002-2003	96
Table 5.29:	Projected sales of Schering-Plough's asthma/COPD R&D pipeline (\$m), 2007 & 2010	96
Table 5.30:	US/European* sales of AstraZeneca's marketed asthma/COPD portfolio (\$m), 2002-2003	98
Table 5.31:	Projected sales of AstraZeneca's asthma/COPD R&D pipeline (\$m), 2007 & 2010	98
Table 5.32:	US/European* sales of Novartis' marketed asthma/COPD portfolio (\$m), 2002-2003	100
Table 5.33:	Projected sales of Novartis' asthma/COPD R&D pipeline (\$m), 2007 & 2010	100
Table 5.34:	US/European* sales of Sepracor's marketed asthma/COPD portfolio (\$m), 2002-2003	102
Table 5.35:	Projected sales of Sepracor's asthma/COPD R&D pipeline (\$m), 2007 & 2010	103
Table 5.36:	Projected sales of Altana's asthma/COPD R&D pipeline (\$m), 2007 & 2010	105